With two approved radioligand therapies on its commercial roster and a recent plan to boost its manufacturing for radiotherapeutics, Novartis AG tapped Ratio Therapeutics Inc. in a potential $745 million collaboration aimed at developing a somatostatin receptor 2 radiotherapeutic for cancer.